Abiopharma

🔍 Yea Christopher (Executive)

Company: KalVista Pharmaceuticals, Inc. (KALV)

Report Date: 2025-08-21

Detailed Transactions and Holdings:

• Acquired 3,750 shares of Common Stock (Direct)
  Date: 2025-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 133,243.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,362 shares of Common Stock at $13.2228 per share (Direct)
  Date: 2025-08-22 | Code: S | equity_swap_involved: 0 | shares_owned_after: 130,881.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 3,750 shares of Restricted Stock Unit (Derivative)
  Date: 2025-08-21 | Code: M | equity_swap_involved: 0 | shares_owned_after: 52,500.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
• F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
• F3: 1/16th of the total restricted stock units subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 21, 2025, subject to continued service through each vesting date.